Chemical Reprogramming of Pluripotent Stem Cells for Faster hCiPSC Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating human chemically induced pluripotent stem cells (hCiPSCs) are inefficient and slow, taking nearly two months to achieve a high yield, and some somatic cell lines are refractory to existing chemical conditions, with additional intrinsic barriers preserving somatic cell fate, hindering rapid reprogramming.
Innovation Solution
A chemical reprogramming method using specific inhibitors such as GSK-3, TGFβ receptor, c-Jun kinase, and other factors to convert epithelial-like cells into pluripotent stem cells, bypassing genetic modification and reducing the duration to less than 50 days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical reprogramming is used to generate hCiPSCs, then genetic modification is avoided and cell safety is improved, but reprogramming efficiency and speed remain insufficient
Solution Approach 1:
The patent applies parameter changes by systematically optimizing chemical reprogramming conditions, including the use of specific inhibitor combinations (GSK-3, TGFβ receptor, c-Jun kinase inhibitors) and precise timing protocols. This resolves the contradiction by improving reprogramming efficiency through parameter optimization while maintaining the safety advantages of chemical methods over genetic modification.
Solution Approach 2:
The patent introduces intermediary substances (chemical inhibitors and small molecules) that mediate the reprogramming process. These intermediaries facilitate the transition from somatic cells to pluripotent stem cells without direct genetic modification, thereby maintaining cell safety while improving reprogramming efficiency through the mediating action of optimized chemical compounds.
2Adaptability or versatility
If current chemical reprogramming conditions are applied, then some somatic cell lines can be reprogrammed, but refractory cell lines remain resistant due to intrinsic barriers
Solution Approach 1:
The patent segments the reprogramming process into distinct stages with specific chemical interventions at each phase. By dividing the reprogramming timeline and applying different chemical inhibitors at specific stages (e.g., GSK-3 inhibitor in early stages, TGFβ receptor inhibitor in later stages), the method addresses intrinsic barriers in refractory cell lines more effectively, improving both adaptability across cell types and robustness of reprogramming.
Solution Approach 2:
The patent implements dynamic chemical reprogramming protocols that adapt to different cell line characteristics. The methodology allows for flexible adjustment of chemical concentrations, timing, and combinations based on the specific refractory cell line being reprogrammed, thereby improving both the adaptability to different cell types and the robustness of the reprogramming outcome.
3Quantity of substance
If traditional reprogramming methods are used, then pluripotent stem cells can be generated, but the process takes nearly two months and scalability is limited
Solution Approach 1:
The patent applies continuous chemical treatment protocols that maintain reprogramming conditions throughout the entire process without interruption. By ensuring continuous action of the chemical inhibitors and small molecules throughout the reprogramming timeline, the method improves stem cell yield while significantly reducing the overall duration from nearly two months to less than 50 days, thereby resolving the contradiction between quantity and time.
Solution Approach 2:
The patent incorporates preliminary chemical treatments that prepare somatic cells for subsequent reprogramming steps. By applying chemical inhibitors and small molecules in advance to prime the cells, the method enhances the overall efficiency and speed of reprogramming, thereby increasing stem cell yield while reducing the total time required without compromising the quantity of cells produced.
4Productivity
If genetic modification is used to generate stem cells, then reprogramming efficiency can be improved, but mutations and immunogenicity are introduced
Solution Approach 1:
The patent replaces the mechanical/genetic system (viral vectors, transposons, CRISPR-Cas9) with a chemical system (small molecules, inhibitors). This substitution achieves reprogramming efficiency comparable to or exceeding genetic methods while eliminating the harmful factors of mutations and immunogenicity associated with genetic modification, thereby resolving the contradiction between productivity and harmful effects.
Data Source
AI summary
Provided herein, in some aspects, are methods and compositions for cell conversion. The methods may convert a cell population comprising one cell type to another cell population comprising another cell type. The converted cell types may have increased cell differentiation potential. The converted cell types can comprise pluripotent stem cells. The compositions provided herein may comprise chemical reprogramming factors for converting cells. The compositions provided herein may comprise chemical reprogramming factors and cells. Also provided herein are reagents for carrying out the methods for converting cells. Additionally, provided herein are methods and compositions for using various cell types obtained by the methods and/or compositions provided herein.